Mario Boccadoro

Research interests

Publications

• Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2312054

• Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

  Journal of Clinical Oncology · 2022 · 10.1200/jco.21.02614

• Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2020.11.014

• Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

  Leukemia · 2020 · https://doi.org/10.1038/s41375-020-0876-z

• Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

  The Lancet Haematology · 2020 · 10.1016/s2352-3026(20)30099-5

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1402888

• Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

  Blood · 2011 · 10.1182/blood-2011-06-358812

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

  Blood · 2011 · 10.1182/blood-2010-10-299529

• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

  Leukemia · 2010 · https://doi.org/10.1038/leu.2010.60

• Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2010.29.8216

• Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

  Blood · 2010 · 10.1182/blood-2010-07-294983

• Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

  Blood · 2008 · 10.1182/blood-2008-04-149427

• International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

  Leukemia · 2008 · 10.1038/leu.2008.307

• MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

  Proceedings of the National Academy of Sciences · 2008 · 10.1073/pnas.0806202105

• Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

  Blood · 2007 · 10.1182/blood-2006-08-036947

• A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma

  New England Journal of Medicine · 2007 · 10.1056/nejmoa065464

• Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

  Leukemia · 2007 · 10.1038/sj.leu.2405062

• Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

  The Lancet · 2006 · 10.1016/s0140-6736(06)68338-4

• International Staging System for Multiple Myeloma

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.04.242

• Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa043445

• Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

  The Hematology Journal · 2003 · 10.1038/sj.thj.6200312

• Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials

  Journal of Clinical Oncology · 1998

• Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy

  New England Journal of Medicine · 1990 · 10.1056/nejm199005173222005

Current projects

No projects listed.